AnaptysBio (NASDAQ:ANAB) Stock Price Up 4.4% – Here’s Why

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price traded up 4.4% on Thursday . The company traded as high as $17.29 and last traded at $17.17. 85,418 shares changed hands during trading, a decline of 84% from the average session volume of 533,342 shares. The stock had previously closed at $16.44.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $22.00 price target on shares of AnaptysBio in a research note on Tuesday, March 4th. BTIG Research lowered shares of AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. JPMorgan Chase & Co. raised their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Wells Fargo & Company raised their price objective on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price objective on shares of AnaptysBio in a report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.11.

AnaptysBio Trading Down 2.8 %

The stock has a market capitalization of $523.79 million, a P/E ratio of -2.81 and a beta of 0.02. The company’s 50-day moving average is $16.80 and its two-hundred day moving average is $22.67.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.89. The firm had revenue of $43.11 million for the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. Sell-side analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Insider Transactions at AnaptysBio

In related news, Director Ecor1 Capital, Llc purchased 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was bought at an average cost of $12.95 per share, with a total value of $86,065.70. Following the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

A number of institutional investors have recently made changes to their positions in ANAB. California State Teachers Retirement System raised its holdings in shares of AnaptysBio by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 1,359 shares in the last quarter. Woodline Partners LP raised its holdings in shares of AnaptysBio by 5.5% in the 4th quarter. Woodline Partners LP now owns 485,073 shares of the biotechnology company’s stock worth $6,422,000 after purchasing an additional 25,094 shares in the last quarter. Soleus Capital Management L.P. bought a new stake in shares of AnaptysBio in the 4th quarter worth approximately $5,481,000. Squarepoint Ops LLC raised its holdings in shares of AnaptysBio by 81.7% in the 4th quarter. Squarepoint Ops LLC now owns 80,870 shares of the biotechnology company’s stock worth $1,071,000 after purchasing an additional 36,365 shares in the last quarter. Finally, Two Sigma Advisers LP raised its holdings in shares of AnaptysBio by 58.1% in the 4th quarter. Two Sigma Advisers LP now owns 293,300 shares of the biotechnology company’s stock worth $3,883,000 after purchasing an additional 107,800 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.